Immune Diseases and Reactions in Drug Discovery

In today's drug discovery's vast and varied landscape, there is an inspiringly open stretch that attracts immense attention - the development of therapies for immune diseases and reactions. These include disorders where the immune system attacks the body itself, as in the case of autoimmune diseases, and hypersensitivity reactions where the immune system overreact, such as allergies. The conditions in question pose significant challenges due to their intricate underlying mechanisms [1-3], involving multiscale immune processes (Fig. 1). However, recent advancements in immunology, coupled with cutting-edge drug design technologies, have paved the way for innovative medications that bring promise for millions of patients worldwide.

Figure 1. Autoimmune disorders result from a multiscale immune response involving diverse cell populations.Adopted from [4].

 The autoimmune diseases mentioned above are disorders where the immune system mistakenly attacks healthy cells and tissues, leading to chronic inflammation and tissue damage [4, 5]. Traditional drug discovery approaches to curing autoimmune diseases have often focused on suppressing the immune response as a whole. However, the confident progress of precision medicine has revolutionized this way of thinking and treatment strategy.

Targeted therapies, such as monoclonal antibodies, permit to “crack the code” and pinpoint specific molecules involved in the immune response, opening the route for the success of more selectively tailored treatments [6, 7]. The continuously emerging, up-to-date therapies rely on a multidisciplinary approach involving immunology, genetics, and drug design and can modulate the immune system's activity while minimizing unwanted side effects.

As a matter of fact, immunotherapy has come to the fore as a groundbreaking approach to treating immune-related disorders. From cancer immunotherapy to autoimmune disease management, these strategies manipulate the immune system to achieve therapeutic outcomes. Harnessing the power of Immunotherapy enabled the practical application of various techniques, including immune checkpoint inhibitors, cytokine-based therapies, and cell-based therapies like CAR-T cells [8-10]. These approaches can restore immune tolerance, modulate immune responses, and reestablish a balance when dealing with autoimmune disorders.

Despite remarkable advancements in immune disease drug discovery and immunotherapy, challenges still persist. Working out therapies that effectively target the immune system without compromising its overall function remains a complex problem to be tackled. Additionally, predicting and managing patients’ variability in response to immunotherapies, as well as immune-related adverse events, is crucial for ensuring the patient's safety.

Undoubtedly, the symbiosis of high-throughput screening, computational modeling, and personalized medicine holds great potential for effectively addressing these challenges. The above tools allow researchers to identify novel drug candidates, optimize their properties, and predict potential immune responses, thus ultimately expediting drug discovery.

Striving to productively contribute to discovering effective treatments for immune diseases, Life Chemicals offers a variety of screening libraries of small drug-like molecules:

• Anti-inflammatory Screening Compound Library
• Immuno-oncology Screening Libraries
• Epigenetic Screening Libraries
• Transcription-related Screening Library
• Apoptosis Signaling Pathway Screening Library
• Hormone-related Focused Library

Please, contact us at marketing@lifechemicals.com for any additional information and price quotations.

Visit our Website for a detailed product description.

Download SD files with compound structures directly from our Downloads section

Custom compound selection based on specific parameters can be performed on request, with competitive pricing and the most convenient terms provided.

References

1. Chen, T., et al. (2016). Developmental origins of inflammatory and immune diseases, Molecular Human Reproduction, 22(8): 858–865, DOI: 10.1093/molehr/gaw036
2. Martino, D.J. and Prescott, S.L. (2010), Silent mysteries: epigenetic paradigms could hold the key to conquering the epidemic of allergy and immune disease. Allergy, 65: 7-15. DOI: 10.1111/j.1398-9995.2009.02186.x
3. Tsuge, K., et al. (2019). Molecular mechanisms underlying prostaglandin E2-exacerbated inflammation and immune diseases, International Immunology, 31(9):597–606, DOI: 10.1093/intimm/dxz021
4. Wang, L, Wang, F-S, Gershwin, M.E. (2015). Human autoimmune diseases: a comprehensive update. J Intern Med 278: 369–395. DOI: 10.1111/joim.12395
5. Persidis, A. (1999). Autoimmune disease drug discovery. Nat Biotechnol 17:1038. DOI: 10.1038/13748
6. Yamada, T. (2011). Therapeutic monoclonal antibodies. The Keio journal of medicine, 60(2), 37-46. DOI: 10.2302/kjm.60.37
7. Tsumoto, K., et al. (2019). Future perspectives of therapeutic monoclonal antibodies, Immunotherapy 11(2): 119-127. DOI: 10.2217/imt-2018-0130
8. Waldmann, T. (2003). Immunotherapy: past, present, and future. Nat Med 9: 269–277. DOI: 10.1038/nm0303-269
9. Patil, S., Gs, V., Sarode, G.S., Sarode, S.C., et al. (2021). Exploring the role of immunotherapeutic drugs in autoimmune diseases: A comprehensive review. J Oral Biol Craniofac Res. 11(2):291-296. DOI: 10.1016/j.jobcr.2021.02.009
10. Caliendo, F., Dukhinova, M., & Siciliano, V. (2019). Engineered cell-based therapeutics: synthetic biology meets immunology. Frontiers in Bioengineering and Biotechnology, 7. DOI: 10.3389/fbioe.2019.00043